

scientific program

MONDAY, SEPT. 9, 2024

17.00 – 18.00

Registration

Opening Session

Chair: Claudia Götz, Karsten Niefind, Joachim Jose

18.00 – 18.30

Welcome addresses

Johannes Wessels, Rector of the University of Münster

Bernhard Wunsch, Director of the Institute of Pharmaceutical and Medicinal Chemistry

Joachim Jose, Chair of the 9th International CK2 Conference

18.30 – 19.00

A journey into the infancy of CK2: serendipitous findings and still open questions

Lorenzo Pinna, University of Padova, Italy

19.00 – 19.30

Evolution of CK2 signaling function since 1994

Khalil Ahmed, Masonic Cancer Center, University of Minnesota, Minneapolis, USA

19.30 – 20.00

Championing change: a parent's journey in redefining OCNDS care and research

Jennifer Sills, CSNK2A1-foundation, San Francisco, USA

20.00 – 22.00

Welcome reception, first face-to-face scientific exchange, further scientific discussions, discussions on the future of the conference & BBQ at PharmaCampus

TUESDAY, SEPT. 10, 2024

8.00 – 8.30

Registration

Session A: CK2 as a cellular pro-survival factor

Chair: Khalil Ahmed

8.30 – 9.00

Cell cycle-dependant activation and genome recruitment of CK2 α

Miwako Homma, Fukushima Medical University, Japan

9.00 – 9.30

CK2 as a cellular pro-survival factor in cancer

Janeen H. Trembley, University of Minnesota, Minneapolis, USA

9.30 – 9.45

Development and uptake of CK2-targeting chemical probes

Alison Axtman, University of North Carolina at Chapel Hill, USA

Session B: CK2 in cancer biology

Chair: Mathias Montenarh

9.45 – 10.15

The potential role of CK2 in dysregulation of mRNA translation in neoplasia

Ivan Topisirovic, McGill University, Montreal, Canada

10.15 – 10.30

CK2 promotes cancer aggressiveness by improving ECE-1C stability upon phosphorylation of its N-terminal end

Julio Tapia, University of Chile, Santiago, Chile

scientific program

TUESDAY, SEPT. 10, 2024

10.30 – 11.00 Coffee break

11.00 – 11.30 **Targeting CK2 in kidney cancer**
Odile Filhol, INSERM, Grenoble, France

11.30 – 12.00 **Regulation of adaptive immune cell function by CK2**
Etty (Tika) Benveniste, University of Alabama, Birmingham, USA

12.00 – 12.30 **CK2 – a therapeutic target for hematopoietic malignancies**
Sinisa Dovat, Pennsylvania State University, College of Medicine, Hershey, USA

12.30 – 12.45 **Protein kinase II (CK2) expression in pediatric solid tumors**
Chandrika Behura, Pennsylvania State University, College of Medicine, Hershey, USA

12.45 – 14.15 Lunch & Poster session

Session C: OCNDS – scientific bases

Chair: Gabrielle Rushing

14.15 – 14.45 **Using mouse models to gain insight into pathological mechanisms of OCNDS**
Heike Rebholz, University of Paris, France

14.45 – 15.15 **CK2 variant specificity in OCNDS and associated online resource development**
Daniel Schwartz, University of Connecticut, Storrs, USA

15.15 – 15.30 **Characterization of CK2 α variants associated with Okur–Chung neurodevelopmental syndrome**
Alexander Gast, University of Münster, Germany

15.30 – 16.15 Coffee break & Poster session

Session D: OCNDS – clinical and translational aspects

Chair: Heike Rebholz

16.15 – 16.45 **CK2 enters the clinical genetics realm: an overview of Okur–Chung neurodevelopmental syndrome**
Volkan Okur, New York Genome Center, New York

16.45 – 17.15 **Using functional prediction programs and the *Xenopus laevis* model to understand OCNDS**
M. Isabel Dominguez, Boston University, USA

17.15 – 17.45 **OCNDS research roadmap: where we were, where we are and where we are headed**
Gabrielle Rushing, CSNK2A1–foundation, San Francisco, USA

17.45 – 19.45 Poster session, finger food & dishes

scientific program

WEDNESDAY, SEPT. 11, 2024

Session E: POBINDS

Chair: Isabel Dominguez

- | | |
|-------------|---|
| 8.30 – 9.00 | Expanding phenotype of Poirier–Bienvenu syndrome: epileptic and neurophysiological phenotype
Alessandro Orsini, U.O.C Pediatria Universitaria, Pisa, Italy |
| 9.00 – 9.30 | Biochemical characterization of CK2β variants linked to POBINDS
Maria Ruzzene, University of Padova, Italy |
| 9.30 – 9.45 | A CK2α' mutant resembling its CK2α isoenzyme in CK2β binding
Christian Werner, Universität zu Köln, Cologne, Germany |

Session F: CK2 in metabolism and cellular homeostasis

Chair: David Litchfield

- | | |
|---------------|---|
| 9.45 – 10.15 | The master facilitator of intrinsic disordered protein assembly and its roles in the fungal pathogen <i>Magnaporthe oryzae</i>
Stefan Olsson, Fujian Agriculture and Forestry University, China |
| 10.15 – 10.45 | Coffee break |
| 10.45 – 11.15 | CK2 function in selective autophagy
Alexandra Stolz, University of Frankfurt/M., Germany |
| 11.15 – 11.45 | Regulation of cell secretome by protein kinase CK2
Mauro Salvi, University of Padua, Padua, Italy |
| 11.45 – 12.15 | CK2 and the cellular metabolism
Mathias Montenarh, Saarland University, Homburg, Germany |
| 12.15 – 12.30 | Role of protein kinase CK2 in adipogenesis: going deeper through inhibition, silencing and genome editing
Anna Pilatone, University of Padua, Italy |

12.30 – 13.30 Lunch & Poster session

scientific program

WEDNESDAY, SEPT. 11, 2024

Session G: CK2 in virus infections

Chair: Maria Ruzzene

- | | |
|---------------|---|
| 13.30 – 14.00 | Towards the CK2 phosphoproteome(s)
David Litchfield, University of Western Ontario, London, Canada |
| 14.00 – 14.30 | Antiviral activity of the clinical-grade CIGB-300 anticancer peptide
Silvio E. Perea, Center for Genetic Engineering and Biotechnology, Havana, Cuba |
| 14.30 – 15.00 | CK2 is a critical regulator of the human papillomavirus 16 life cycle
Iain M. Morgan, Virginia Commonwealth University (VCU), USA |
| 15.00 – 15.15 | Metallacarborane derivatives as a novel class of protein kinase CK2 (and other kinase) inhibitors
Konrad Kubiński, The John Paul II Catholic University of Lublin, Poland |

16.00 – 17.00 Guided City Tour

19.00 – 22.00 Conference Dinner at Mühlenhof Freilichtmuseum Münster

THURSDAY, SEPT. 12, 2024

Session H: Structure, Function and Inhibition

Chair: Claudia Götz, Karsten Niefind, Joachim Jose

- | | |
|---------------|---|
| 8.30 – 9.00 | A hundred and one ways to inhibit CK2α
Marko Hyvönen, University of Cambridge, UK |
| 9.00 – 9.30 | CK2 inhibitors – academia to the clinic
David R. Spring, University of Cambridge, UK |
| 9.30 – 10.00 | “Jumping out of the catalytic box” – in search of new inhibitors of Protein Kinase CK2
Markus Pietsch, Univ. of Appl. Science Cologne, Germany |
| 10.00 – 10.15 | Tumor-selective cell death induction by AB668, a bivalent CK2 inhibitor
Claude Cochet, Institut de Recherche Interdisciplinaire de Grenoble, France |
| 10.15 – 10.30 | From CK2 inhibition to fluorescent labelling and targeted protein degradation
Claire Coderch, Fundación Universitaria San Pablo CEU, Madrid, Spain |

10.30 – 11.00 Coffee break

scientific program

THURSDAY, SEPT. 12, 2024

11.00 – 11.30	Bringing together drug design and linkerology: application to CK2 inhibitors Marc Le Borgne, University of Lyon, France
11.30 – 12.00	The importance of being bisubstrate: construction of potent inhibitors of CK2 Asko Uri, University of Tartu, Estonia
12.00 – 12.30	Thermodynamics of ligand binding at the ATP binding site of the catalytic subunit of PK CK2 Maria Winiewska-Szajewska, Institute of Biochemistry and Biophysics, Warsaw, Poland
12.30 – 13.00	Poster and best short presentation awards/concluding remarks/next CK2 conference?
13.00	End of Conference

Awards will be given for the best poster and oral presentations.